Persistent hepatic encephalopathy secondary to portosystemic shunt occluded with Amplatzer device
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 4
Abstract
Hepatic encephalopathy is a frequent complication of cirrhosis, when this event becomes persistent, treatment compliance should be verified and any precipitating factor need to be identified. Also the presence of portosystemic shunts, which are a rare cause of decompensation or persistence hepatic encephalopathy need to be ruled out. In this paper we report the case of a 57 year old man with persistent hepatic encephalopathy secondary to the presence of a porto-onfalo-femoral shunt successfully closed with the placement of an Amplatzer device.
Authors and Affiliations
Ariadna Ramírez-Polo, Ernesto Márquez-Guillén, Adrián J. González-Aguirre, Iván E. Casanova-Sánchez, Rafael Chávez-Ruiz, Eduardo Carrillo-Maravilla, Eric López-Méndez
Keywords
Related Articles
- EP ID EP78425
- DOI -
- Views 118
- Downloads 0
Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis
Background. Bacterial infections are often associated with significant morbidity and mortality in cirrhosis. The common practice of outdoor barefoot walking in the developing world may predispose cirrhotic individuals to...
Right hepatic artery aneurysms in a child with Kawasaki disease: flow-preserving endovascular treatment
Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant biliary obstruction
Ursodeoxycholic acid (UDCA) is the first choice medication for most cholestatic hepatopathies, due to its capability to counteract inflammation and bile-acid-induced liver damage, two common features in cholestasis. How...
Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas
Background and objective. Steatohepatitis is a common cause of liver disease due to alcohol (ALD) or non-alcoholic fatty liverdisease (NAFLD). We performed this study to compare natural history of ALD and NAFLD. Material...
Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects
Introduction. CYP2D6 is a liver enzyme that metabolizes more that 25% of drugs and thus may play a pivotal role in drug-drug interactions. The promoter sequences of cytochrome P450 2D6 (CYP2D6) gene could impact metaboli...